APP
SRPT icon

Avantax Planning Partners’s Sarepta Therapeutics SRPT Stock Holding History

Avantax Planning Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-169
Closed -$27K – 1069
2018
Q3 		$27K Buy
+169
New +$23.1K ﹤0.01% 633
2018
Q2 		– Sell
-99
Closed -$7K – 1304
2018
Q1 		$7K Buy
+99
New +$6.6K ﹤0.01% 1219

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Avantax Planning Partners's SRPT Position: Q4 2018 in Review

Avantax Planning Partners sold out of Sarepta Therapeutics (SRPT) in Q4 2018, closing a stake of 169 shares — an estimated $27K sold.

Avantax Planning Partners first reported a position in SRPT in Q1 2018 and held it in 2 quarters. The position peaked at $27K in Q3 2018. 336 funds tracked by Wall St. Rank hold SRPT as of Q4 2018.

  • Avantax Planning Partners reported no remaining Sarepta Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 169 Sarepta Therapeutics shares in Q4 2018, an estimated $27K.
  • Avantax Planning Partners first reported a position in Sarepta Therapeutics in Q1 2018 and held it in 2 quarters.
  • Avantax Planning Partners's Sarepta Therapeutics position peaked at $27K in Q3 2018.
  • 336 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2018.

Based on Avantax Planning Partners's 13F filing for Q4 2018, filed 14 Feb 2019.